Findings from the randomized phase II CURB trial indicate that using stereotactic body radiation therapy to target oligoprogression in patients with non–small cell lung cancer significantly prolongs progression-free survival compared with standard systemic treatment. However, the same approach does not benefit patients with breast cancer.

中文翻译：

---

高度聚焦的辐射可能会抑制寡进展

随机 II 期 CURB 试验的结果表明，与标准全身治疗相比，使用立体定向全身放射治疗来靶向非小细胞肺癌患者的寡进展可显着延长无进展生存期。然而，同样的方法并不能让乳腺癌患者受益。